Oxbridge Clinical key facts
as of Oct 2026- Manufacturer of diagnostic equipment designed for the identification of pathogens across a variety of sample types.
- Oxbridge Clinical is valued at approximately $22.5M as of Oct 2026, set at its seed round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $5.5M across 1 recorded rounds; the latest was Seed Round ($4.5M) in Oct 2025.
- Notable investors include The Engine, Accelerate Cambridge, BioTools Innovator, Steele Foundation for Hope.
- Status: Privately Held (backing).
Valued at $22.5M at its seed round, Oct 2025. Nothing has traded since.
- ·Watch Oxbridge Clinical: the Monday email on marks, rounds and moves
Oxbridge Clinical funding rounds
1 roundsWho backs Oxbridge Clinical
4Oxbridge Clinical valuation
Oxbridge Clinical was valued at $22.5 million at its seed round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Oxbridge Clinical raised?
Oxbridge Clinical has raised $5.5 million across 1 recorded round since 2025. The largest was a $4.5 million seed round in Oct 2025.
Oxbridge Clinical investors
4 investors are on record for Oxbridge Clinical, including The Engine, Accelerate Cambridge, BioTools Innovator and Steele Foundation for Hope. The seed round in Oct 2025 drew 3 investors.
About Oxbridge Clinical
Manufacturer of diagnostic equipment designed for the identification of pathogens across a variety of sample types. The company's technology uses solid-state nanopores to differentiate among various germs that cause respiratory infections, which often present with similar symptoms, enabling healthcare professionals at the point of care to obtain rapid, cost-effective, and specific diagnoses.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Employees
- 2
- Website
- oxbridgeclinical.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.